Pfizer Inc. (NYSE:PFE) Shares Sold by Lowe Brockenbrough & Co. Inc.

Lowe Brockenbrough & Co. Inc. reduced its stake in Pfizer Inc. (NYSE:PFE) by 39.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 158,978 shares of the biopharmaceutical company’s stock after selling 103,314 shares during the period. Lowe Brockenbrough & Co. Inc.’s holdings in Pfizer were worth $4,218,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently made changes to their positions in the company. Retirement Wealth Solutions LLC acquired a new stake in shares of Pfizer in the 4th quarter worth approximately $26,000. Rialto Wealth Management LLC acquired a new stake in shares of Pfizer in the 4th quarter worth approximately $26,000. Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Pfizer in the 4th quarter worth approximately $28,000. Noble Wealth Management PBC acquired a new stake in Pfizer during the fourth quarter valued at approximately $31,000. Finally, Curio Wealth LLC acquired a new stake in Pfizer during the fourth quarter valued at approximately $32,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Performance

Shares of PFE opened at $26.17 on Friday. The company’s fifty day moving average is $26.18 and its 200-day moving average is $27.07. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The firm has a market cap of $148.29 billion, a price-to-earnings ratio of 18.56, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same period last year, the business posted $0.10 EPS. Pfizer’s revenue was up 24.7% compared to the same quarter last year. Equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Insider Buying and Selling at Pfizer

In related news, Director Ronald E. Blaylock purchased 19,457 shares of Pfizer stock in a transaction on Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 0.06% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently commented on PFE shares. Truist Financial reduced their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. Citigroup reduced their price target on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Guggenheim restated a “buy” rating on shares of Pfizer in a research report on Tuesday. Finally, UBS Group reduced their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.